文献速递临床试验与 GCP

微创与开放胰十二指肠切除术治疗胰腺及壶腹周围肿瘤(DIPLOMA-2):国际多中心患者盲法随机对照试验研究方案

Minimally invasive versus open pancreatoduodenectomy for pancreatic and peri-ampullary neoplasm (DIPLOMA-2): study protocol for an international multicenter patient-blinded randomized controlled trial.
PubMed 文献 · Trials · 2023-10-12

DIPLOMA-2试验为国际随机对照、患者盲法、非劣效性研究,在欧洲14个高容量胰腺中心开展,计划纳入288例因癌前或恶性病变行择期胰十二指肠切除术的患者,按2:1随机分配至微创或开放手术。主要结局为术后90天内综合并发症指数(CCI®),非劣效界值7.5分;主要次要结局为功能恢复时间,将进行优效性分析。

要点

  • 微创胰十二指肠切除术(MIPD)安全性尚存争议,功能恢复时间缩短有待证实。
  • DIPLOMA-2试验比较MIPD与开放胰十二指肠切除术(OPD),主要终点为90天CCI®。
  • 假设MIPD在总体并发症方面非劣于OPD,在功能恢复时间方面优于OPD。

核心结论

  • DIPLOMA-2试验旨在确立MIPD作为高容量中心特定患者胰十二指肠切除术新标准治疗的安全性,最终追求更优的患者康复。

研究设计与样本

  • 国际随机对照、患者盲法、非劣效性试验,在欧洲14个高容量胰腺中心开展,各中心年手术量至少30例MIPD和30例OPD。
  • 计划纳入288例因癌前或恶性疾病行择期胰十二指肠切除术、适合开放和微创两种入路的患者,按2:1随机分配至MIPD或OPD。
  • 各中心根据外科专长实施腹腔镜或机器人辅助MIPD。

主要发现

  • 主要结局为综合并发症指数(CCI®),测量术后90天内所有按Clavien-Dindo分级评估的并发症。
  • 样本量计算假设:单侧显著性水平2.5%(α)、80%把握度(1-β)、MIPD与OPD平均CCI®评分预期差值为0分、非劣效界值为7.5分。
  • 主要次要结局为功能恢复时间,将进行优效性分析。
  • 其他次要结局包括术后90天Fitbit™测量的活动量、手术结局(如失血量、手术时间、中转开放手术、外科医生报告结局)、恶性肿瘤的肿瘤学结局(如R0切除率、辅助治疗时间、生存)、术后结局(如临床相关并发症)、医疗资源利用(住院时间、再入院、重症监护时间)、生活质量和费用。
  • 术后随访长达36个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimally invasive pancreatoduodenectomy (MIPD) aims to reduce the negative impact of surgery as compared to open pancreatoduodenectomy (OPD) and is increasingly becoming part of clinical practice for selected patients worldwide. However, the safety of MIPD remains a topic of debate and the potential shorter time to functional recovery needs to be confirmed. To guide safe implementation of MIPD, large-scale international randomized trials comparing MIPD and OPD in experienced high-volume centers are needed. We hypothesize that MIPD is non-inferior in terms of overall complications, but superior regarding time to functional recovery, as compared to OPD. METHODS/DESIGN: The DIPLOMA-2 trial is an international randomized controlled, patient-blinded, non-inferiority trial performed in 14 high-volume pancreatic centers in Europe with a minimum annual volume of 30 MIPD and 30 OPD. A total of 288 patients with an indication for elective pancreatoduodenectomy for pre-malignant and malignant disease, eligible for both open and minimally invasive approach, are randomly allocated for MIPD or OPD in a 2:1 ratio. Centers perform either laparoscopic or robot-assisted MIPD based on their surgical expertise. The primary outcome is the Comprehensive Complication Index (CCI®), measuring all complications graded according to the Clavien-Dindo classification up to 90 days after surgery. The sample size is calculated with the following assumptions: 2.5% one-sided significance level (α), 80% power (1-β), expected difference of the mean CCI® score of 0 points between MIPD and OPD, and a non-inferiority margin of 7.5 points. The main secondary outcome is time to functional recovery, which will be analyzed for superiority. Other secondary outcomes include post-operative 90-day Fitbit™ measured activity, operative outcomes (e.g., blood loss, operative time, conversion to open surgery, surgeon-reported outcomes), oncological findings in case of malignancy (e.g., R0-resection rate, time to adjuvant treatment, survival), postoperative outcomes (e.g., clinically relevant complications), healthcare resource utilization (length of stay, readmissions, intensive care stay), quality of life, and costs. Postoperative follow-up is up to 36 months. DISCUSSION: The DIPLOMA-2 trial aims to establish the safety of MIPD as the new standard of care for this selected patient population undergoing pancreatoduodenectomy in high-volume centers, ultimately aiming for superior patient recovery. TRIAL REGISTRATION: ISRCTN27483786. Registered on August 2, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. de Graaf N, Emmen AMLH, Ramera M, et al. Minimally invasive versus open pancreatoduodenectomy for pancreatic and peri-ampullary neoplasm (DIPLOMA-2): study protocol for an international multicenter patient-blinded randomized controlled trial. Trials. 2023. PMID: 37828593. doi:10.1186/s13063-023-07657-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。